Mounjaro

Tesla Inc. (NASDAQ:TSLA) has been surpassed in market value by pharmaceutical giant Eli Lilly (NYSE:LLY), following a 12% single-day plunge in Tesla’s stock. What Happened: Tesla’s fourth-quarter earnings report, which fell short of revenue and profit expectations, triggered a...

Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices for a month’s supply of these drugs were high then, and in 2024 their manufacturers have raised them higher still. According to data by 46brooklyn...

Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...

How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market...

Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics...

Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have dominated headlines in 2023 with increased interest and the impact being discussed by food and drink companies. Here's a look at the consumer segments that might be driving the enthusiasm and demand for these GLP-1 drugs. What...

Eli Lilly & Co. (NYSE:LLY) has been a high-flier among the mega-cap pharma stocks this year, as the company leverages the obesity drug craze. Prominent Tesla investor and Future Fund Manager Gary Black weighed in on the stock’s run-up and its future trajectory. What Happened: Lilly stock...

Jim Cramer does not recommend investors to buy Eli Lilly (NASDAQ:LLY) stocks yet, despite the recent jump, CNBC reports. Responding to an email query, Cramer mentioned a new 12-month price target of $600 for Eli Lilly. Despite the promising outlook, the rapid ascent of Eli Lilly’s stock has...

Eli Lilly & Co. (NYSE:LLY) jumped nearly 15% to a new record on Tuesday, as the biopharma's stock rode on two catalysts. Lilly reported second-quarter earnings and revenue that were way ahead of expectations and it raised its full-year guidance. The shares also benefited from positive data...

Novo Nordisk and Eli Lilly and Co. (NYSE:LLY), manufacturers of diabetes drugs Ozempic and Mounjaro, are facing a lawsuit over claims of causing gastroparesis, CBS News reports. The lawsuit, filed by personal injury law firm Morgan & Morgan, alleges a “failure to warn” about the...

The race to develop weight-loss drugs more potent than the popular Ozempic is heating up, with several promising contenders on the horizon, The Wall Street Journal reports. Novo Nordisk’s (NYSE:NVO) Ozempic and Eli Lilly’s (NYSE:LLY) Mounjaro have seen a surge in demand due to their...

A new clinical trial has shown that Mounjaro, a diabetes drug similar to Ozempic and Wegovy, could be a game-changer in the field of weight loss, Insider reports. Mounjaro, developed by Eli Lilly and Co. (NYSE:LLY), was approved for treating type 2 diabetes in May 2022. The latest data suggests...

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) is due to announce results from a late-stage trial, dubbed SELECT, that evaluates its semaglutide, sold under the brand name Wegovy, for the reduction of cardiovascular events in overweight or obese non-diabetic patients with prior cardiovascular...